PBAC's latest decision on National hepatitis c data collection: Noted (2019). Considered for This is a status report on the National Hepatitis C Data Collection (REACH-C study), which monitors the real-world cost-effectiveness and health outcomes of direct-acting antiviral (DAA) medicines for chronic hepatitis C treatment.
PBAC outcome
Noted
Not applicable
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2019
Submissions
1
2019 → 2019
Eligible population
Patients with chronic hepatitis C treated with direct-acting antiviral (DAA) medicines from 1 March 2016 onwards, across tertiary and non-tertiary settings including general practice.
Therapy area
Hepatology
Line of therapy
Not applicable
Evidence base
Registry
Primary endpoint
Surrogate
Pivotal trial size
5,416 patients
Key trials
REACH-C
Economic model
Not modelled
Eligible patients/year
5,416
ICER note
This is a data collection progress report, not a drug submission with an economic evaluation.